Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

January 26, 2017
An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay, head of Informa Pharma Intelligence Products, shares with Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.
Previous Video
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duva...

Next Video
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Glob...